Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 89

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
.5 million for the same period in 2024, a decline of approximately $239,000, or 7%. The reduction
was primarily attributable to lower order volumes and timing differences in recurring purchases from certain online distributors.

International revenue for the nine months ended
September 30, 2025, was approximately $2.9 million compared to $2.7 million for the
same period in 2024, an increase of approximately $211,000, or 8%.

Sales
in China for the nine months ended September 30, 2025, were approximately $310,000, compared to no sales in the same period of 2024.
The increase reflects the Company’s successful efforts to reestablish operations and distribution channels in the region following
prior-year market disruptions.

Medical revenue also increased, totaling approximately $125,000 for the
nine months ended September 30, 2025, compared to $74,000 in the prior-year period, representing an increase of approximately $51,000,
or 69%. The increase primarily reflects ongoing progress in expanding the clinical use and adoption of the CompuFlo® Epidural and
CathCheck® Systems within the pain management and anesthesia markets.

Gross
Profit for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $4,783,111  
    $4,859,275  
    $(76,164)
  
    Medical 
     122,800  
     64,251  
     58,549 
  
    Total gross profit 
    $4,905,911  
    $4,923,526  
    $(17,615)

Consolidated gross profit for the nine months ended September 30, 2025,
and 2024 was approximately $4.9 million for each period, reflecting no material change year over year. Stable gross profit performance
was primarily the result of consistent product margins, favorable manufacturing cost management, and a balanced sales mix between domestic
and international markets.

Despite modest fluctuations in regional and product-level revenue, the
Company maintained gross margin stability through ongoing operational efficiencies, disciplined pricing strategies, and continued supply
chain optimization.

Selling,
general and administrative expenses for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $